Leerink Partners Forecasts Strong Price Appreciation for Elevance Health (NYSE:ELV) Stock

Elevance Health (NYSE:ELV) had its price objective upped by equities researchers at Leerink Partners from $350.00 to $357.00 in a research note issued on Thursday,MarketScreener reports. The brokerage presently has a “market perform” rating on the stock. Leerink Partners’ target price points to a potential upside of 3.29% from the company’s current price.

Several other equities research analysts also recently commented on the stock. UBS Group set a $400.00 target price on shares of Elevance Health in a research note on Thursday. Deutsche Bank Aktiengesellschaft reissued a “hold” rating and issued a $332.00 target price on shares of Elevance Health in a research report on Thursday. TD Cowen reissued a “buy” rating on shares of Elevance Health in a research report on Wednesday, November 26th. Wolfe Research set a $425.00 price objective on Elevance Health and gave the stock an “outperform” rating in a research note on Thursday, January 8th. Finally, Wells Fargo & Company cut their target price on shares of Elevance Health from $424.00 to $391.00 and set an “overweight” rating for the company in a research note on Friday. Twelve research analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $398.16.

Elevance Health Stock Performance

Shares of Elevance Health stock opened at $345.62 on Thursday. The firm has a 50 day simple moving average of $351.69 and a 200 day simple moving average of $329.03. The firm has a market cap of $76.81 billion, a P/E ratio of 13.76, a P/E/G ratio of 1.88 and a beta of 0.51. Elevance Health has a fifty-two week low of $273.71 and a fifty-two week high of $458.75. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.54 and a quick ratio of 1.56.

Elevance Health (NYSE:ELV) last released its earnings results on Wednesday, January 28th. The company reported $3.33 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.10 by $0.23. The company had revenue of $49.31 billion for the quarter, compared to the consensus estimate of $49.52 billion. Elevance Health had a net margin of 2.84% and a return on equity of 15.59%. The company’s revenue was up 9.6% compared to the same quarter last year. During the same period in the prior year, the company posted $3.84 EPS. Elevance Health has set its FY 2026 guidance at 25.500- EPS. Sell-side analysts predict that Elevance Health will post 33.96 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Elevance Health

A number of hedge funds have recently made changes to their positions in ELV. Delta Investment Management LLC lifted its stake in shares of Elevance Health by 21.5% in the 4th quarter. Delta Investment Management LLC now owns 28,692 shares of the company’s stock valued at $10,058,000 after acquiring an additional 5,080 shares during the last quarter. Simplicity Wealth LLC grew its stake in shares of Elevance Health by 20.0% in the fourth quarter. Simplicity Wealth LLC now owns 1,220 shares of the company’s stock worth $428,000 after purchasing an additional 203 shares during the last quarter. Joel Isaacson & Co. LLC grew its stake in shares of Elevance Health by 45.1% in the fourth quarter. Joel Isaacson & Co. LLC now owns 2,561 shares of the company’s stock worth $898,000 after purchasing an additional 796 shares during the last quarter. Pekin Hardy Strauss Inc. increased its holdings in Elevance Health by 448.0% in the fourth quarter. Pekin Hardy Strauss Inc. now owns 9,618 shares of the company’s stock valued at $3,372,000 after purchasing an additional 7,863 shares during the period. Finally, Keybank National Association OH raised its position in shares of Elevance Health by 1.5% during the fourth quarter. Keybank National Association OH now owns 9,104 shares of the company’s stock worth $3,191,000 after acquiring an additional 132 shares during the last quarter. 89.24% of the stock is currently owned by institutional investors and hedge funds.

Elevance Health News Summary

Here are the key news stories impacting Elevance Health this week:

• Positive Sentiment: Q4 earnings beat consensus (EPS beat and strong profit print), which sparked an earlier rally and helped lift investor sentiment. Elevance Health (NYSE:ELV) Stock Price Up 6.3% on Strong Earnings
• Positive Sentiment: Leerink Partners nudged its price target up to $357 and maintained a “market perform” rating, a modest vote of confidence that signals upside potential from current levels. Leerink Partners adjusts price target on Elevance Health to $357
• Positive Sentiment: Consensus broker sentiment remains constructive (average “Moderate Buy”), which provides some support for the shares as analysts digest results and guidance. Elevance Health, Inc. Given Average Recommendation of “Moderate Buy”
• Neutral Sentiment: Company Q4 call and published highlights provide detail on membership shifts, margin dynamics and the drivers behind the quarter — useful for longer-term modeling but not a clear immediate catalyst. ELV Q4 2025 Earnings Call Highlights
• Negative Sentiment: Management forecast for 2026 profit came in below some Street estimates and flagged an anticipated revenue decline, which is the principal near-term headwind pressuring the stock. Elevance forecasts 2026 profit below estimates
• Negative Sentiment: Analysts and commentary highlighted margin pressures and membership shifts shaping a weaker 2026 outlook — narratives that have driven selloffs despite the quarterly beat. ELV Q4 Deep Dive: Margin Pressures and Membership Shifts
• Negative Sentiment: Regulatory context: a CMS proposal for only a modest Medicare Advantage rate increase added to near-term investor concern, contributing to a large negative move earlier in the week. Health Insurance Stock Could Rebound Off Historically Bullish Signal
• Negative Sentiment: Coverage pieces framed the results as “in line” but stressed the deteriorating outlook and ongoing industry headwinds, which has kept selling pressure on the shares after the initial post-earnings bounce. Elevance reports Q4 in line with expectations but stock drops

Elevance Health Company Profile

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.